Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated December 11, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on December 10, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established via a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. No revenue, profit, cash flow, or debt metrics are provided in this specific document.
- Shares Purchased (Dec 10, 2025): 220,000 ordinary shares.
- Price Range: Lowest 1,771.00 GBp; Highest 1,807.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,789.73 GBp.
- Programme Progress: Since September 30, 2025, the Company has purchased 12,944,733 ordinary shares.
- Treasury Holdings: Following this purchase, GSK holds 238,409,577 ordinary shares in treasury.
- Shares in Issue: 4,077,029,560 ordinary shares (excluding Treasury shares).
- Treasury Voting Rights: 5.85% of total voting rights.
Material Changes
The filing does not present comparative financial performance data against prior periods. The primary change reported is the reduction of shares in issue and the increase in treasury shares resulting from the December 10 repurchase activity.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties. These risks are referenced as being detailed in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q3 Results for 2025.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on September 30, 2025.
- Confirm the impact of the 5.85% treasury holding on earnings per share (EPS) calculations.
- Review the referenced 2024 Form 20-F and 2025 Q3 Results for detailed risk factors and operational context.
- Monitor future 6-K filings for subsequent repurchase activity under the non-discretionary agreement.